Company Overview

Biogen is a global biopharmaceutical company focused on discovering, developing, and delivering innovative therapies for people living with serious and complex diseases. It pioneers innovative science to deliver new medicines and transform patients' lives. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen has 7,605 employees and a market capitalization of $21.07 billion as of September 2025.

Core Business Operations

The company has a broad portfolio of medicines to treat multiple sclerosis (MS), has introduced the first approved treatment for spinal muscular atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease, and launched the first approved treatment to target a genetic cause of ALS. Biogen also markets the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia (FA) in adults and adolescents aged 16 years and older.

Primary Product Portfolio

- Multiple Sclerosis Products: TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI.

- Rare Disease Treatments:

- SPINRAZA for spinal muscular atrophy

- SKYCLARYS to treat Friedreich's Ataxia

- QALSODY for treating amyotrophic lateral sclerosis (ALS)

- Other Key Products:

- FUMADERM to treat plaque psoriasis

- LEQEMBI for early Alzheimer's disease (co-developed with Eisai)

- ZURZUVAE for depression

Geographic Presence

Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

Financial Performance

2024 Financial Highlights

- Annual Results:

- Full year 2024 total revenue was $9.7 billion, a 2% decline year-over-year.

- GAAP diluted EPS was $11.18, a 40% growth year-over-year.

- Non-GAAP diluted EPS (Full Year 2024) was $16.47, 12% higher than 2023.

- Free cash flow (Full Year 2024) was $2.7 billion, up from $1.3 billion in 2023.

- Q4 2024 Results:

- Total revenue for Q4 2024 was $2.5 billion, reflecting a 3% increase year-over-year.

- GAAP diluted earnings per share (EPS) rose by 7% year-over-year to $1.83.

- Non-GAAP diluted EPS saw a significant 17% boost, reaching $3.44.

Key Product Performance

- LEQEMBI (Alzheimer's):

- Robust sales with fourth-quarter global sales reaching approximately $87 million.

- 66% growth in global revenue in the third quarter compared to the second quarter.

- SKYCLARYS (Friedreich's Ataxia):

- Strong performance with global revenue of $102 million in Q4 2024.

- The SKYCLARYS launch is progressing well, generating revenue in 15 countries outside the US.

- ZURZUVAE (Depression):

- Outperformed expectations in the US, with a 49% increase in revenue over the second quarter.

Financial Position

- End of 2024: $2.4 billion cash, $3.9 billion net debt.

- EPS (TTM): $10.48.

2025 Outlook and Guidance

- Revenue Guidance: Expected to decline by a mid-single-digit percentage.

- Non-GAAP Diluted EPS Guidance: Between $15.25 and $16.25.

- The company anticipates a mid-single-digit percentage decline in total revenue for 2025 compared to 2024, primarily due to expected decreases in multiple sclerosis product revenue.

Strategic Initiatives

Cost Optimization Program

The "Fit for Growth" program is expected to generate approximately $1 billion of gross savings and $800 million net of reinvestment by the end of 2025. Since its initiation in 2023, approximately $400 million of net savings have been achieved.

Recent Acquisitions

On July 2, 2024, Biogen completed the acquisition of all shares of HI-Bio, a clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. HI-Bio's lead asset, felzartamab, is currently being evaluated for three leading indications.

Pipeline and Development Focus

Biogen is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The company has a strong late-stage pipeline with potential peak sales of about $14 billion. Biogen launched four first-in-class, disease-modifying products in Alzheimer's, Friedreich's ataxia, depression, and ALS in recent years.

Key development programs include:

- LEQEMBI intravenous maintenance dosing approved by FDA; subcutaneous maintenance dosing BLA filing.

- Nusinersen (SPINRAZA) higher dose regimen for SMA filings accepted by FDA and EMA.

- Dapirolizumab pegol second Phase 3 study initiated in systemic lupus erythematosus.

Collaborations and Partnerships

The company has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc.

Investment Considerations

Revenue from new product launches in 2024 more than offset the decline in multiple sclerosis product revenue, marking the first core pharma business growth in four years. However, the company faces continued challenges from MS product revenue decline (roughly 8% at actual currency, 9% at constant currency in Q4 2024) and increasing competition in its core franchises.

The company remains optimistic about the growth potential from its ongoing product launches and late-stage pipeline. Biogen aims to maintain a flat operating margin percentage for 2025.